3050 Spruce Street, St. Louis, MO 63103 USA
Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757
email: techservice@sial.com sigma-aldrich.com

Product Information

HumanKine™ Platelet derived growth factor-AA human, recombinant expressed in HEK 293 cells

Catalog Number **H8291**
Storage Temperature –20 °C

Synonym: PDGF-AA

Product Description

HumanKine™ recombinant human PDGF-AA, expressed in human 293 cells, is a mixture of pro-form, pro-mature, and mature dimers with apparent molecular masses of 35, 40, and 45 kDa, respectively. They are disulfide linked glycosylated homodimers. Production in human 293 cells offers authentic glycosylation. Glycosylation contributes to stability in cell growth media and other applications.

Platelet-Derived Growth Factor (PDGF), first identified in serum[1] is the principal mitogen present for cells of mesenchymal origin.[2,3] PDGF is localized in α-granules of platelets and released during clot formation.[4] PDGF from human platelets has been purified and described as a cationic glycoprotein (pI 9.5–10.4) having a molecular mass of ~30 kDa and composed of two covalently linked subunits, designated as chains A (16 kDa) and B (14 kDa).[5-8] In platelets, ~70% of the PDGF is present as the AB dimer, with most of the remainder as BB.[9] Purified human PDGF shows substantial size heterogeneity, ranging from 27–31 kDa, probably due to the presence of isoforms, glycosylation processing, aging of the platelets, and partial proteolysis during purification.

The A and B chains are 40% homologous in sequence and are encoded by distinctly different genes.[10] Each chain contains 8 cysteine residues, which are involved in intra- and inter-chain disulfide bonds.[11,12] Cleavage of these bonds by reduction causes irreversible loss of biological activity.[8] PDGF is believed to play an essential role in the cellular response to tissue injury, both as a stimulant of mesodermal cell growth and activity, and as a chemoattractant to other cells involved in the repair process.[16]

In this role, PDGF appears to interact with Transforming Growth Factor-β1 (TGF-β1), which is also released by degranulating platelets at the source of the damaged tissue.[17] The sources of PDGF during wound repair include platelets (predominantly PDGF-AB), smooth muscles (PDGF-A),[18] monocyte-derived macrophages (PDGF-B),[19] and endothelial cells (PDGF- B).[20] PDGF may play a role during normal embryonic development.[14]

Pathologically, PDGF appears to be an initial mediator and a contributing sustaining factor in the development of atherosclerosis.[18-21] Abnormal cellular expression of PDGF is associated with certain malignant transformations.[13] In fact, a transforming protein (p28sis) encoded by the simian sarcoma virus oncogene (*v-cis*) contains a section that is virtually identical to PDGF-B in its amino acid sequence,[23] is processed into a PDGF-BB-like homodimer,[24] and exhibits biological actions identical to PDGF.[25] Detection of *v-cis*-related mRNA (*c-sis* RNA) has been reported in certain malignancies of mesenchymal cell origin, including fibrosarcoma, glioblastoma, and osteosarcoma.[26,27] PDGF-A chain or both A and B chains are expressed by certain other tumor cell lines.[10,28] Other pathological conditions in which PDGF has been implicated include scleroderma, inflammatory joint disease, myelofibrosis, and pulmonary fibrosis.[9,14]

Purified PDGF activates two distinct PDGF receptors encoded by separate genes.[29,30] PDGF-AA binds only to α-PDGF receptor but PDGF-AB and PDGF-BB bind to both α and β receptors; i.e., the α receptor binds either A or B chain and the β receptor binds only the B chain.[29,31]

Perhaps the independent expression of specific receptor types and the availability of the different isoforms of PDGF may explain the diverse range of observed cellular PDGF responses.[30] For example, the PDGF-B gene has a much greater transforming potential than the PDGF-A gene when transfected into NIH 3T3 cells, but the PDGF-A gene product is more efficiently secreted into the medium.[32]

The sequence domains on each chain responsible for the greater receptor activation and secretory ability have been recently mapped.[33] Furthermore, certain tumors have been found to express the β-PDGF receptor with or without the coexpression of the PDGF-B chain, indicating a tumor may be autocrinically growth stimulated[34] or stimulated by exogenous PDGF.[35] Binding of either PDGF receptor to its substrate induces receptor autophosphorylation at a tyrosine residue,[31] which then becomes detectable by immunoreaction with Monoclonal Anti-Phosphotyrosine.

This product is lyophilized from a solution of 10 mM acetic acid.

ED_{50}: ≤2,000 ng/mL

The specific activity was determined by the dose-dependent stimulation of the proliferation of 3T3 cells.

Purity: ≥95% (SDS-PAGE)

Endotoxin level: ≤1 EU/µg

Precautions and Disclaimer
This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions
Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein in sterile 4 mM HCl containing 0.1% endotoxin-free recombinant human serum albumin.

Storage/Stability
Store the product at –20 °C. The lyophilized product remains active for one year at –20 °C.

Upon reconstitution, the cytokine can be stored at 2–8 °C for short term only, or at –20 °C to –80 °C in aliquots for long term. Avoid repeated freeze-thaw cycles.

References

1. Ross, R., and Glomset, J.A., Science, **180**, 1332 (1973).
2. Ross, R., et al., Proc. Natl. Acad. Sci. USA, **71**, 1207 (1974).
3. Kohler, N., and Lipton, A., Exp. Cell Res., **87**, 297 (1974).
4. Kaplan, D.R., et al., Blood, **53**, 1043 (1979).
5. Antoniades, H.N., et al., Proc. Natl. Acad. Sci. USA, **76**, 1809 (1979).
6. Heldin, C.H., et al., Proc. Natl. Acad. Sci. USA, **76**, 3722 (1979).
7. Deul, T.F., et al., J. Biol. Chem., **256**, 8896 (1981).
8. Raines, E.W., and Ross, R., J. Biol., **257**, 5154 (1982).
9. Ross, R., Lancet, **27,** 1179 (1989).
10. Betsholtz, C., et al., Nature, **320**, 695 (1986).
11. Giese, N.A., et al., Science, **236**, 1315 (1987).
12. Sauer, M.K., and Donoghue, D., Mol. Cell. Biol., **8**, 1011 (1988).
13. Antoniades, H.N., and Pantazis, P., Methods Enzymol., **169**, 210 (1989).
14. Ross, R., et al., Cell, **46**, 155 (1986).
15. Heldin, C.H., et al., Mol. Cell. Endocrinol., **39**, 169 (1985).
16. Barnes, D., Methods Enzymol., **163**, 707 (1988).
17. Pierce, G.F., et al., J. Cell Biol., **109**, 429 (1989).
18. Barrett, T.B., and Benditt, E.P., Proc. Natl. Acad. Sci. USA, **85**, 2810 (1988).
19. Ross, R., et al., Science, **248**, 1009 (1990).
20. Collins, T., Nature, **316**, 748 (1985).
21. Ross, R., et al., Arterioclerosis, **1**, 293 (1981).
22. Schwartz, S.M., and Ross, R., Prog. Cardiovasc. Dis., **26**, 355 (1984).
23. Waterfield, M.D., et al., Nature, **304**, 35 (1983).
24. Robbins, K., et al., EMBO J., **4**, 1783 (1985).
25. Johnsson, A., et al., Proc. Natl. Acad. Sci. USA, **82**, 1721 (1985).
26. Graves, D.T., et al., Science, **226**, 972 (1984).
27. Pantazis, P., et al., Proc. Natl. Acad. Sci. USA, **82**, 2404 (1985).
28. Heldin, C.H., et al., Nature, **319**, 511 (1986).
29. Matsui, T., et al., Science, **243**, 800 (1989).
30. Matsui, T., et al., Proc. Natl. Acad. Sci. USA, **86**, 8314 (1989).
31. Hart, C.E., et al., Science, **240**, 1529 (1988).
32. Beckmann, M.P., et al., Science, **241**, 1346 (1988).
33. LaRochelle, W.J., et al., Science, **248**, 1541 (1990).
34. Hermansson, M., et al., Proc. Natl. Acad. Sci. USA, **85**, 7748 (1988).
35. Heldin, N.-E., et al., Proc. Natl. Acad. Sci. USA, **85**, 9302 (1988).

GS,JF,MAM 12/10-1